In mid January, the FDA approved Intelence (etravirine, TMC-125) for treatment of HIV. The new non-nuke aims to help those positive people whose virus is resistant to the other three meds in that class—Sustiva, Viramune and Rescriptor; it has not been approved for people just starting meds. The dose is two 100 mg tablets twice a day in a combo with drugs from other classes. Intelence, whose most common side effects in trials were rash and nausea, can’t be teamed with the other non-nukes, nor with some protease inhibitors. Details at AIDSmeds.com (search for “Intelence”) or your doctor’s office.
New Med in Town
The FDA approves an HIV med, expanding the non-nuke class.